A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera

Ropeginterferon alfa-2b represents a new-generation pegylated interferon-based therapy and is administered every 2–4 weeks. It is approved for polycythemia vera (PV) treatment in the United States and Europe with a starting dose of 100 µg (50 µg for patients receiving hydoxyurea) and intra-patient d...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Jie, Zhang, Lei, Qin, Albert, Wu, Daoxiang, Shao, Zonghong, Bai, Jie, Chen, Suning, Duan, Minghui, Zhou, Hu, Xu, Na, Zhang, Sujiang, Zuo, Xuelan, Du, Xin, Wang, Li, Li, Pei, Zhang, Xuhan, Li, Yaning, Zhang, Jingjing, Wang, Wei, Shen, Weihong, Zagrijtschuk, Oleh, Urbanski, Raymond, Sato, Toshiaki, Xiao, Zhijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286412/
https://www.ncbi.nlm.nih.gov/pubmed/37344895
http://dx.doi.org/10.1186/s40164-023-00415-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286412/
https://www.ncbi.nlm.nih.gov/pubmed/37344895
http://dx.doi.org/10.1186/s40164-023-00415-0

Ejemplares similares